The stock of Amicus Therapeutics Incorporated (NASDAQ:FOLD) registered an increase of 2.99% in short interest. FOLD’s total short interest was 25.12 million shares in March as published by FINRA. Its up 2.99% from 24.39 million shares, reported previously. With 2.02M shares average volume, it will take short sellers 13 days to cover their FOLD’s short positions. The short interest to Amicus Therapeutics Incorporated’s float is 25.59%. The stock is down 4.14% or $0.33 after the news, hitting $7.65 per share. About 2.01M shares traded hands. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has declined 51.58% since July 28, 2015 and is downtrending. It has underperformed by 46.48% the S&P500.
Amicus Therapeutics, Inc. is a biopharmaceutical company. The company has a market cap of $1.12 billion. The Firm focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders . It currently has negative earnings. The Company’s lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
The institutional sentiment decreased to 1.39 in Q3 2015. Its down 0.28, from 1.67 in 2015Q2. The ratio fall, as 20 funds sold all Amicus Therapeutics, Inc. shares owned while 41 reduced positions. 24 funds bought stakes while 61 increased positions. They now own 132.64 million shares or 17.79% more from 112.61 million shares in 2015Q2.
Venbio Select Advisor Llc holds 15.46% of its portfolio in Amicus Therapeutics, Inc. for 4.25 million shares. Perceptive Advisors Llc owns 14.44 million shares or 14.04% of their US portfolio. Moreover, Longwood Capital Partners Llc has 11.38% invested in the company for 1.40 million shares. The New York-based Apis Capital Advisors Llc has invested 5.74% in the stock. Sectoral Asset Management Inc, a Quebec - Canada-based fund reported 6.11 million shares.
Since March 24, 2015, the stock had 2 insider buys, and 6 selling transactions for $4.10 million net activity. Perceptive Advisors Llc bought 50,000 shares worth $313,500. Peist Kenneth sold 10,000 shares worth $131,362. Quimi Daphne sold 11,250 shares worth $147,761. Campbell Bradley L sold 13,001 shares worth $218,206. The insider Baird William D Iii sold 15,236 shares worth $255,634.
Out of 5 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 4 rate it “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Amicus Therapeutics was the topic in 7 analyst reports since August 18, 2015 according to StockzIntelligence Inc.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.